ensitrelvir

Also known as 1-(2,4,5-trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione, S-217622

thumb|right|75px|Xocova in a Japanese blister pack

Key facts

Drug.image: Ensitrelvir.svg
Drug.image_class: skin-invert-image
Drug.tradename: Xocova
Drug.routes_of_administration: By mouth
Drug.ATC_prefix: J05
Drug.ATC_suffix: AE11
Drug.legal_status: JP: Rx-only
Drug.elimination_half life: 42–48 hours
Drug.CAS_number: 2647530-73-0
Drug.CAS_number2: 2757470-18-9
Drug.PubChem: 162533924
Drug.DrugBank: DB18834
Drug.ChemSpiderID: 115007411
Drug.UNII: PX665RAA3H
Drug.KEGG: D12353
Drug.synonyms: S-217622
Drug.IUPAC_name: 1-(2,4,5-Trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione
Drug.C: 22

via Wikipedia infobox

Wikidata facts

Mass: 531.1145831240002

Show 3 more facts

canonical SMILES: Cn1cnc(CN2C(=O)N(Cc3cc(F)c(F)cc3F)C(=N\c3cc4cn(C)nc4cc3Cl)\NC2=O)n1
Commons category: Ensitrelvir
chemical formula: C₂₂H₁₇ClF₃N₉O₂

Sources (1)

bio.nikkeibp.co.jp

via Wikidata · CC0

~5 min read

Article

7 sections

Contents

Medical uses
History
Society and culture
Legal status
Names
Research
References

thumb|right|75px|Xocova in a Japanese blister pack

Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth.